Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

BLA FilingOzekibartPositive

AI Analysis

Summary

Inhibrx announced FDA acceptance of a Biologics License Application (BLA) for Ozekibart in patients with conventional chondrosarcoma. This regulatory milestone moves the drug toward potential approval.

Outcome Details

FDA acceptance of BLA

Importance:7/10

Sentiment:

0.70

BLA acceptanceFDAoncologychondrosarcoma

Related Companies

$INBX

Read the original article

Published by yahoo_finance on June 15, 2026 1:15 PM

Read Original